Document Detail

Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense.
MedLine Citation:
PMID:  16238799     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The physicochemical modification of allergen extracts provides a chance for administering higher doses of allergen vaccines. OBJECTIVE: To evaluate the safety of a chemically modified (depigmented-glutaraldehyde polymerized) therapeutic vaccine of Phleum pratense administered at doses that are 10 times higher than those used in clinical practice, in comparison with conventional doses of the corresponding non-modified alum-adsorbed vaccine. MATERIALS AND METHODS: The design of the study was randomized, double-blind, parallel and included two groups of patients. Twenty-three patients were treated weekly during nine visits for the build-up phase, followed by two weekly maintenance doses (a total of 11 injections per patient). Twelve patients received a vaccine containing the standardized unmodified extract, at a maximum concentration of 308.5 mcg of freeze dried material/mL (Group A). Eleven patients received a standardized modified allergen extract (Group B). The maximum dose used was 2400 mcg/mL. Safety was evaluated recording all adverse events. Skin test results and specific antibody levels were evaluated at the beginning and at the end of the study. RESULTS: Group A patients experienced three local immediate (two clinically irrelevant and one with a diameter>5 cm) and 18 delayed reactions (15 irrelevant and three with a diameter>10 cm), while Group B experienced six local immediate and 12 delayed reactions (all clinically irrelevant). Nine Group A patients experienced 12 systemic reactions (one immediate of grade 1, one of grade 2; and one delayed of grade 1; four of grade 2 and three of grade 3), while Group B patients experienced one immediate systemic reaction of grades 1, and 1 delayed reaction of grade 1. CONCLUSIONS: The modified extract of P. pratense is safe to treat sensitive patients, even at concentrations that are 10 times higher than those regularly administered in clinical practice. The majority of the local reactions were clinically irrelevant. No systemic reactions of grade 2, 3 or 4 were reported using the modified extract.
M Casanovas; J Sastre; M Fernández-Nieto; M Lluch; J Carnés; E Fernández-Caldas
Related Documents :
18533549 - Post-surgical role of botulinum toxin-a injection in patients with head and neck cancer...
19481579 - Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in ...
3524119 - A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin an...
12428839 - Botulinum toxin a in anal fissures: a modified technique.
16000649 - Quantification of intravenously administered contrast medium transit through the periph...
19918859 - Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointme...
15142349 - Cd4+ t-cell recovery and clinical outcome in hiv-1-infected patients exposed to multipl...
18088349 - Partial factor ixa inhibition with ttp889 for prevention of venous thromboembolism: an ...
23644079 - Early administration of azathioprine vs conventional management of crohn's disease: a r...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology     Volume:  35     ISSN:  0954-7894     ISO Abbreviation:  Clin. Exp. Allergy     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-21     Completed Date:  2006-02-09     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8906443     Medline TA:  Clin Exp Allergy     Country:  England    
Other Details:
Languages:  eng     Pagination:  1377-83     Citation Subset:  IM    
Laboratorios LETI, S.L., Tres Cantos, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Allergens / administration & dosage,  chemistry,  immunology
Asthma / immunology,  therapy
Chemistry, Physical
Conjunctivitis, Allergic / immunology,  therapy
Desensitization, Immunologic / adverse effects,  methods*
Dose-Response Relationship, Immunologic
Double-Blind Method
Electrophoresis, Polyacrylamide Gel
Hypersensitivity, Immediate / immunology,  therapy*
Immunoglobulin E / biosynthesis
Immunoglobulin G / biosynthesis
Middle Aged
Phleum / immunology*
Physicochemical Phenomena
Rhinitis, Allergic, Seasonal / immunology,  therapy
Skin Tests
Reg. No./Substance:
0/Allergens; 0/Immunoglobulin G; 37341-29-0/Immunoglobulin E
Erratum In:
Clin Exp Allergy. 2005 Dec;35(12):1651-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
Next Document:  Comparison of purified Dermatophagoides pteronyssinus allergens and extract by two-dimensional immun...